| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 1,000 | 0 | - | 122 |
| Total revenue-Research And Development Services | - | 0 | - | - |
| Research and development | 9,601 | 9,923 | 7,837 | 14,828 |
| General and administrative | 8,157 | 13,175 | 17,688 | 15,037 |
| Total costs and expenses | 17,758 | 23,098 | 25,525 | 29,865 |
| Loss from operations | -16,758 | -23,098 | -25,525 | -29,743 |
| Interest income | 144 | 364 | 621 | 1,357 |
| Change in fair value of warrant liabilities | 2,369 | -1,437 | -3,104 | 40,184 |
| Other expense | -7 | -33 | -25 | -21 |
| Total other income (expense), net | -2,232 | 1,768 | 3,700 | -38,848 |
| Net loss | -18,990 | -21,330 | -21,825 | -68,591 |
| Earnings per share, basic | -0.13 | -0.15 | -0.15 | -0.48 |
| Earnings per share, diluted | -0.13 | -0.15 | -0.15 | -0.48 |
| Weighted average number of shares outstanding, basic | 145,559,604 | 145,091,474 | 144,787,971 | 144,345,781 |
| Weighted-average common stock outstanding - diluted (in shares) | 145,559,604 | 145,091,474 | 144,787,971 | 144,345,781 |
Applied Therapeutics, Inc. (APLT)
Applied Therapeutics, Inc. (APLT)